1. Recommendations for the treatment of established RA (disease duration 6 month or longer). Biologic, biological originator DMARD or boDMARD; DMARD, disease-modifying antirheumatic drug (In this figure, “DMARD” refers to conventional synthetic DMARDs or csDMARDs); HCQ, hydroxychloroquine; LEF, leflunomide; MTX, methotrexate; TNF, tumor necrosis factor. aSee Ref. 19 for definitions of disease activity. bCombination DMARD therapy: methotrexate + leflunomide, methotrexate + hydroxychloroquine, methotrexate + sulfasalazine, sulfasalazine + hydroxychloroquine. Triple DMARD therapy: methotrexate + hydroxychloroquine + sulfasalazine. cReassess after 3 months of adequate therapy. dReassess after 6 months of adequate therapy. (Reproduced, with permission, from Singh JA, Furst DE, Bharat A, et al Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64:625–639.)
Source: Rheumatoid Arthritis, Pharmacotherapy Principles & Practice, 4e
Citation: Chisholm-Burns MA, Schwinghammer TL, Wells BG, Malone PM, Kolesar JM, DiPiro JT. Pharmacotherapy Principles & Practice, 4e; 2016 Available at: Accessed: December 24, 2017
Copyright © 2017 McGraw-Hill Education. All rights reserved